Research programme: viral haemorrhagic fevers therapeutics - Arisan Therapeutics
Latest Information Update: 16 Jan 2024
At a glance
- Originator Arisan Therapeutics
- Developer Arisan Therapeutics; National Institute of Allergy and Infectious Diseases
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Viral haemorrhagic fevers
Most Recent Events
- 13 Sep 2023 Early research in Viral haemorrhagic fevers in USA (PO) before September 2023 (Arisan Therapeutics pipeline, September 2023)